Strategic positioning Target AIS interventional markets with a focus on neurointerventional devices and physicians' collaboration, highlighting MIVI's proprietary technology aimed at improving safety and efficacy in acute ischemic stroke therapy to differentiate from competitors.

Growth signals With revenue in the low millions and a funding total of 92 million, pursue larger hospital systems and regional centers of excellence that can scale adoption of next generation neurointerventional devices.

Leadership access Engage senior clinical and commercial leaders recently added to the team, such as VP of clinical affairs and VP of commercial field development, to accelerate clinical trials, key opinion leader engagement, and field-facing education programs.

Clinical partnerships Leverage prior executive hires from Medtronic and other large players to propose collaborative studies, post-market surveillance, and comparative effectiveness research to support adoption and reimbursement efforts.

Funding leverage Position MIVI as a growth-stage partner capable of multi-site evaluation and pilot deployments in teaching hospitals, academic centers, and regional stroke programs to unlock broader purchasing commitments.